Pelthos Therapeutics Inc. (PTHS)

ASE – Real vaqt narxi. Valyuta: USD

27.24

+0.39 (1.45%)

Yopilishda: May 12, 2026, 3:59 PM EDT

31.03.2026

Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease

19.03.2026

Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript

19.03.2026

Pelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue Estimates

Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $2.83 per share versus the Zacks Consensus Estimate of a loss of $3.95. This compares to a loss of $3.2 per share a year ago.

19.03.2026

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

ZELSUVMI ™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December 31, 2025. Total revenue including licensing revenue was $16.8 million for 2025.

12.03.2026

Pelthos Therapeutics to Present at 38th Annual ROTH Conference

DURHAM, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that CEO Scott Plesha will participate in a fireside chat at the 38th Annual ROTH Conference on March 23, 2026 at 3:00 p.m. Pacific Time.

15.01.2026

Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

FARMINGTON, Conn.--(BUSINESS WIRE)--Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”) (the “Company”), an affiliate of Monroe Capital, today announced it has provided a $50 million venture loan facility to Pelthos Therapeutics Inc. (NYSE American: PTHS) (“Pelthos”), with an initial funding of $30 million, and up to $20 million to support future growth. Pelthos is a publicly traded biopharmaceutical company that is licensed to commercialize ZELSUVMI™ (berdazimer) topical gel, an.

13.01.2026

Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

The minimally dilutive funding will accelerate Pelthos' highly successful commercialization efforts for its lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3% for the treatment of molluscum contagiosum, two newly acquired FDA approved cutaneous infectious disease products and for working capital and general corporate purposes The minimally dilutive funding will accelerate Pelthos' highly successful commercialization efforts for its lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3% for the treatment of molluscum contagiosum, two newly acquired FDA approved cutaneous infectious disease products and for working capital and general corporate purposes

Videolar

No Data

There is no data to display

Press-relizlar

31.03.2026

Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease

19.03.2026

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

15.01.2026

Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

13.01.2026

Pelthos Therapeutics Inc. (PTHS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Pelthos Therapeutics Inc. (PTHS)

Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript

Pelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue Estimates

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

Pelthos Therapeutics to Present at 38th Annual ROTH Conference

Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

Videolar

No Data

Press-relizlar

Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript

Pelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue Estimates

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

Pelthos Therapeutics to Present at 38th Annual ROTH Conference

Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

Videolar

No Data

Press-relizlar

Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

Search stocks

Pelthos Therapeutics Inc. (PTHS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Pelthos Therapeutics Inc. (PTHS)

Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript

Pelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue Estimates

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

Pelthos Therapeutics to Present at 38th Annual ROTH Conference

Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

Videolar

No Data

Press-relizlar

Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript

Pelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue Estimates

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

Pelthos Therapeutics to Present at 38th Annual ROTH Conference

Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

Videolar

No Data

Press-relizlar

Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance